Concepedia

Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin – Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial)

Gregory Y.H. Lip, Naab Al‐Saady, James Jin, Ming Sun, Michael Melino, Shannon M. Winters, Dmitry Zamoryakhin, Andreas Goette

The American Journal of Cardiology · 2017 · 16 citations · 14 references

DOIFull text

Open access

Concepts

References

14

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

Gregory Y.H. Lip, Robby Nieuwlaat, Ron Pisters et al. · CHEST Journal · 2009 · 6.7K citations · Full text

, , +16

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

Ron Pisters, Deirdre A. Lane, Robby Nieuwlaat et al. · CHEST Journal · 2010 · 4.5K citations · Full text

, , +14

A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

F.R. Rosendaal, Suzanne C. Cannegieter, F.J.M. van der Meer et al. · Thrombosis and Haemostasis · 1993 · 2.1K citations · Full text

, , +14

Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin

Stavros Apostolakis, Renee M. Sullivan, Brian Olshansky et al. · CHEST Journal · 2013 · 478 citations

, , +16

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Andreas Goette, José Luís Merino, Michael D. Ezekowitz et al. · The Lancet · 2016 · 246 citations

, , +12